Kuntal Baveja’s Post

A few days ago, Novartis completed the acquisition of Chinook Therapeutics, a Seattle-based biopharmaceutical company specializing in the discovery, development and commercialization of precision medicines for kidney diseases. This deal includes two late-state assets to treat a progressive, rare kidney disease that mostly affects young adults and currently lacks targeted treatment options - which is not only a strong sign of further growth for Novartis, but more importantly a demonstration of our full focus on innovation. A few months ago, we embarked on this journey to become a technological leader in research and development - globally and also in Austria. Now this is another important step in that direction #Novartis #Innovation #InnovativeMedicines #ReimaginingMedicine